Biotech Values

[biomaven0]

At the end of the day CRME's drug is for something of a niche indication compared with the wide usage that amiodarone has despite its absolutely miserable side effect profile. Amiodarone is basically the drug of choice in heart failure patients with atrial fib (which is between 15-30% of all heart failure patients) because unlike other atrial fib drugs it has no negative inotropic effects. Amiodarone has to be a candidate for the trickiest-to-use and most toxic widely-used non-oncology drug.

So the comparison isn't really a good one. If Budiodarone is an easier-to-use amiodarone that works in a good percentage of HF patients with atrial fib, it would find wide use as a first-line agent, with amiodarone reserved for patients that don't respond. So it clearly has at least potential as a significant blockbuster, although it's still too early to project its ultimate efficacy and S/E profile and hence how it will actually play out.